KZR
Kezar Life Sciences Inc

1,700
Loading...
Loading...
News
all
press releases
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
Zacks·4mo ago
News Placeholder
More News
News Placeholder
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it...
Business Wire·7mo ago
News Placeholder
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial...
Business Wire·10mo ago
News Placeholder
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
Glancy Prongay & Murray LLP (GPM) announces its investigation of Kezar Life Sciences, Inc. (Nasdaq: KZR) concerning the Company and its directors and officers possible violations of state laws. If...
Business Wire·10mo ago
News Placeholder
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it...
Business Wire·11mo ago
News Placeholder
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study
Kezar Life Sciences halted its PALIZADE Phase 2b lupus nephritis trial due to fatal adverse events. Meanwhile, its PORTOLA Phase 2a autoimmune hepatitis trial progresses, with topline data expected...
Benzinga·11mo ago
News Placeholder
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its...
Business Wire·11mo ago
News Placeholder
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced key...
Business Wire·11mo ago
News Placeholder
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal
Kezar Life Sciences, Inc. (Kezar or the Company) (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today...
Business Wire·11mo ago
News Placeholder
Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was...
Business Wire·1y ago

Latest KZR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.